BR0108962A - Formulações de ácido nucléico para distribuição de genes e métodos de uso - Google Patents
Formulações de ácido nucléico para distribuição de genes e métodos de usoInfo
- Publication number
- BR0108962A BR0108962A BR0108962-5A BR0108962A BR0108962A BR 0108962 A BR0108962 A BR 0108962A BR 0108962 A BR0108962 A BR 0108962A BR 0108962 A BR0108962 A BR 0108962A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- polyacid
- methods
- acid formulations
- gene distribution
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 229920006318 anionic polymer Polymers 0.000 abstract 2
- 229920002230 Pectic acid Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- -1 anionic amino acid Chemical class 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 239000010318 polygalacturonic acid Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçõES DE áCIDO NUCLéICO PARA DISTRIBUIçãO DE GENES E MéTODOS DE USO". Descreve-se uma formulação de ácido nucléico para uso em distribuição de genes, compreendendo um ácido nucléico e um polímero aniónico. Os exemplos do polímero aniónico incluem polímero de aminoácido aniónico ou poliaminoácido (como o poliácido (L-glutâmico), poliácido (D-glutâmico), poliácido (L-aspártico), poliácido (D-aspártico), poliácido acrílico, polinucleotídeos, ácido poligalacturónico e polissulfato de vinila.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18723600P | 2000-03-03 | 2000-03-03 | |
US26175101P | 2001-01-16 | 2001-01-16 | |
PCT/US2001/006953 WO2001066149A2 (en) | 2000-03-03 | 2001-03-02 | Nucleic acid formulations for gene delivery and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108962A true BR0108962A (pt) | 2002-12-24 |
Family
ID=26882847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108962-5A BR0108962A (pt) | 2000-03-03 | 2001-03-02 | Formulações de ácido nucléico para distribuição de genes e métodos de uso |
Country Status (9)
Country | Link |
---|---|
US (2) | US7173116B2 (pt) |
EP (1) | EP1259265B1 (pt) |
JP (1) | JP4987205B2 (pt) |
AT (1) | ATE511400T1 (pt) |
AU (1) | AU2001245427A1 (pt) |
BR (1) | BR0108962A (pt) |
CA (1) | CA2401327C (pt) |
DK (1) | DK1259265T3 (pt) |
WO (1) | WO2001066149A2 (pt) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040192593A1 (en) * | 1999-07-26 | 2004-09-30 | Baylor College Of Medicine | Protease resistant ti-growth hormone releasing hormone |
US6551996B1 (en) * | 1999-07-26 | 2003-04-22 | Baylor College Of Medicine | Super-active porcine growth hormone releasing hormone analog |
CA2423093C (en) | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
BR0213965A (pt) * | 2001-10-26 | 2005-03-15 | Baylor College Medicine | Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo |
WO2003059382A2 (en) * | 2001-12-28 | 2003-07-24 | Supratek Pharma Inc. | Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression |
MXPA04011766A (es) * | 2002-05-28 | 2005-03-31 | Advisys Inc | SUMINISTRO AUMENTADO DE UNA CONSTRUCCION DE áCIDO NUCLEICO IN VIVO POR EL SISTEMA DE POLO-L-GLUTAMATO (PLG). |
US20040014645A1 (en) * | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
US20080269153A1 (en) * | 2002-05-28 | 2008-10-30 | Ruxandra Draghia-Akli | Increased stability of a dna formulation by including poly-l-glutamate |
DE60336736D1 (de) * | 2002-07-16 | 2011-05-26 | VGX Pharmaceuticals LLC | Codon-optimierte synthetische plasmide |
AU2003302337A1 (en) * | 2002-12-31 | 2004-07-29 | The Johns Hopkins University | Wound healing method and kits |
US20040204358A1 (en) * | 2003-01-28 | 2004-10-14 | Advisys, Inc. | Reducing culling in herd animals growth hormone releasing hormone (GHRH) |
EP1601776B1 (en) * | 2003-03-11 | 2008-07-02 | Laboratoires Serono SA | Expression vectors comprising the mcmv ie2 promoter |
AU2004229465B2 (en) * | 2003-04-09 | 2010-04-29 | The United States Of America Department Of Veterans Affairs | Compositions and methods related to production of erythropoietin |
TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
US20090005333A1 (en) * | 2004-01-26 | 2009-01-01 | Vgx Pharmaceuticlas, Inc. | Reducing culling in herd animals growth hormone releasing hormone (ghrh) |
EP2438931B1 (en) * | 2004-09-22 | 2013-11-13 | St. Jude Children's Research Hospital | Improved expression of factor IX in gene therapy vectors |
TWI294460B (en) * | 2004-12-23 | 2008-03-11 | Ind Tech Res Inst | Method for stabilizing nucleic acids |
US20060094023A1 (en) * | 2004-11-02 | 2006-05-04 | Industrial Technology Research Institute | Method for isolating nucleic acid by using amino surfactants |
CN101370927A (zh) * | 2005-12-07 | 2009-02-18 | 基因特伦尼克斯公司 | 可变容积电穿孔室以及其方法 |
JP2009528131A (ja) * | 2006-03-03 | 2009-08-06 | ジェネトロニクス,インコーポレイティド | 外科的切除後の組織に残る微視的残余腫瘍の処置方法及び装置 |
EP2799547B1 (en) | 2006-11-08 | 2016-12-21 | Veritas Bio, LLC | In Vivo Delivery of RNA to a Target Cell |
FR2941152B1 (fr) * | 2009-01-20 | 2013-10-18 | Centre Nat Rech Scient | Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques. |
WO2012018594A2 (en) * | 2010-07-26 | 2012-02-09 | Scott & White Healthcare | Plant-derived polysaccharides for delivery of rna-based therapies |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP2741785B1 (en) | 2011-07-12 | 2018-09-05 | Philadelphia Health and Education Corporation | Novel clostridium difficile dna vaccine |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
KR102014061B1 (ko) | 2011-10-03 | 2019-08-28 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
EP3747898B1 (en) | 2012-02-22 | 2023-03-15 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
ES2959443T3 (es) | 2012-02-22 | 2024-02-26 | Univ Pennsylvania | Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación |
AU2013243947A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
ES2786263T3 (es) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
ES2902839T3 (es) * | 2012-10-08 | 2022-03-30 | Biontech Delivery Tech Gmbh | Derivados de poliaminas carboxiladas como reactivos de transfección |
CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
PT2956477T (pt) | 2013-02-15 | 2021-02-05 | Bioverativ Therapeutics Inc | Gene do fator viii otimizado |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
EA201790953A1 (ru) | 2014-10-31 | 2017-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Изменение экспрессии гена в cart-клетках и их применения |
JP6884697B2 (ja) | 2014-10-31 | 2021-06-09 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | T細胞を刺激および拡大する組成物および方法 |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
EP4223873A3 (en) | 2015-01-31 | 2023-09-06 | The Trustees of the University of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
RU2754661C2 (ru) | 2015-05-01 | 2021-09-06 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Гликанзависимые иммунотерапевтические молекулы |
EP4218777A3 (en) | 2015-08-28 | 2023-08-23 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
AU2018396083A1 (en) | 2017-12-29 | 2020-05-21 | Cellectis | Method for improving production of CAR T cells |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
CN113661180A (zh) | 2019-03-27 | 2021-11-16 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
US20210322471A1 (en) | 2020-03-27 | 2021-10-21 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
US20210324332A1 (en) | 2020-03-27 | 2021-10-21 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2022056490A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
EP4240405A1 (en) | 2020-11-05 | 2023-09-13 | Mendus B.V. | Use of tumor-independent antigens in immunotherapies |
EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
CA3230933A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4543252A (en) * | 1982-01-21 | 1985-09-24 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
AU2698684A (en) * | 1983-07-01 | 1985-02-07 | Battelle Memorial Institute | Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments |
DE3581471D1 (de) * | 1984-10-19 | 1991-02-28 | Battelle Memorial Institute | Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten. |
US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
JP3368603B2 (ja) * | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | 遺伝子治療用処置具 |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
AU6714094A (en) | 1993-04-28 | 1994-11-21 | Ribozyme Pharmaceuticals, Inc. | Ocular delivery of nucleic acid |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
FR2715847B1 (fr) * | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US6271205B1 (en) * | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
US6040295A (en) * | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
FR2732218B1 (fr) * | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US6048551A (en) * | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
US6040925A (en) | 1997-12-12 | 2000-03-21 | Hewlett-Packard Company | Radial and pruned radial interpolation |
US6383811B2 (en) * | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
WO2000002621A1 (en) * | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US7396919B1 (en) * | 1998-07-17 | 2008-07-08 | Mirus Bio Corporation | Charge reversal of polyion complexes |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
FR2786098B1 (fr) * | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
EP1189971B1 (en) | 1999-06-17 | 2005-03-09 | Universiteit Gent | Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application |
AU5624400A (en) | 1999-06-18 | 2001-01-09 | Collaborative Group, Ltd., The | Hyaluronic acid film and matrix for sustained gene transfer |
EP1209971A4 (en) | 1999-08-20 | 2004-04-14 | Mirus Corp | POLYION COMPLEX LOAD INVERSION |
EP1309904A4 (en) * | 2000-03-03 | 2006-03-29 | Valentis Inc | IMPROVED POLOXAMER AND POLYOAMINE COMPOUNDS FOR NUCLEINE SUCTION INTRODUCTION |
CA2423093C (en) * | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
-
2001
- 2001-03-02 BR BR0108962-5A patent/BR0108962A/pt not_active IP Right Cessation
- 2001-03-02 JP JP2001564801A patent/JP4987205B2/ja not_active Expired - Lifetime
- 2001-03-02 CA CA2401327A patent/CA2401327C/en not_active Expired - Lifetime
- 2001-03-02 EP EP01918339A patent/EP1259265B1/en not_active Expired - Lifetime
- 2001-03-02 AU AU2001245427A patent/AU2001245427A1/en not_active Abandoned
- 2001-03-02 WO PCT/US2001/006953 patent/WO2001066149A2/en active Application Filing
- 2001-03-02 DK DK01918339.1T patent/DK1259265T3/da active
- 2001-03-02 AT AT01918339T patent/ATE511400T1/de not_active IP Right Cessation
-
2002
- 2002-09-03 US US10/234,406 patent/US7173116B2/en not_active Expired - Lifetime
-
2006
- 2006-11-20 US US11/561,847 patent/US7491537B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2401327A1 (en) | 2001-09-13 |
US7173116B2 (en) | 2007-02-06 |
US20070213287A1 (en) | 2007-09-13 |
JP2003525912A (ja) | 2003-09-02 |
ATE511400T1 (de) | 2011-06-15 |
CA2401327C (en) | 2014-05-06 |
EP1259265B1 (en) | 2011-06-01 |
JP4987205B2 (ja) | 2012-07-25 |
EP1259265A2 (en) | 2002-11-27 |
US7491537B2 (en) | 2009-02-17 |
DK1259265T3 (da) | 2011-07-11 |
WO2001066149A2 (en) | 2001-09-13 |
WO2001066149A3 (en) | 2002-03-14 |
AU2001245427A1 (en) | 2001-09-17 |
US20030109478A1 (en) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0108962A (pt) | Formulações de ácido nucléico para distribuição de genes e métodos de uso | |
IL114566A (en) | Compositions containing nucleic acids and cationic polymer and their uses | |
MXPA02008841A (es) | Composiciones cosmeticas que contienen copolimero de acido metacrilico, silicona y polimero cationico y su utilizacion. | |
DE69535576D1 (de) | Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie | |
WO1997025067A3 (en) | Polymers | |
BRPI0412845A (pt) | herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo | |
FI973467A (fi) | DNA-molekyylejä, valmistus ja käyttö geeniterapiassa | |
EP1025217A4 (en) | RECOMBINATORY CLONING USING NUCLEIC ACIDS HAVING RECOMBINATION SITES | |
FR2796392B1 (fr) | Composition nettoyante comprenant un polymere hydrosoluble ou hydrodispersable | |
DE60118933D1 (de) | Matrix zur aufnahme von arzneimitteln | |
YU35498A (sh) | Sintetički hiv geni | |
WO2003064607A3 (en) | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions | |
BR0014663A (pt) | Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias | |
DE69732029D1 (de) | Dna enthaltende impfstoffen | |
ES2092382T3 (es) | Composicion cosmetica en forma de gel acuoso. | |
ATE282433T1 (de) | Kationische kopolymere von vinylamine und vinylalkohol zur verabreichung von oligonukleotiden | |
BR9712362A (pt) | Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon | |
HUT77029A (hu) | A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk | |
TR200100430T2 (tr) | Tyrosine kinase SRC kullanılan angiogenesisin modülasyonu için yararlı metot ve bileşimler. | |
AU2001233957A1 (en) | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression | |
ATE48231T1 (de) | Makromolekulare cdp-cholinderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel. | |
BR0001906A (pt) | Processo para a preparação fermentativa de l-aminoácidos usando bactérias corineformes | |
WO2006014234A3 (en) | Novel recombinant poxvirus composition and uses thereof | |
ATE508736T1 (de) | Mikropartikel zur verabreichung von nukleinsäuren | |
DK0811068T3 (da) | Humane DNase I varianter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |